Legal & General Group
RNA

Legal & General Group’s Atrium Therapeutics RNA Stock Holding History

Legal & General Group’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1K Sell
1,422
-4,235
-75% -$55.3K ﹤0.01% 3138
2026
Q1 		$75.6K Buy
+5,657
New +$79.5K ﹤0.01% 2631

Other funds holding RNA

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Legal & General Group's RNA Position: Q2 2026 in Review

Legal & General Group reduced its Atrium Therapeutics (RNA) stake by 75% in Q2 2026, selling an estimated $55.3K and leaving 1,422 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3138.

Legal & General Group first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. The position peaked at $75.6K in Q1 2026. 155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Legal & General Group held 1,422 shares of Atrium Therapeutics worth $19.1K as of Q2 2026.
  • Legal & General Group sold 4,235 Atrium Therapeutics shares in Q2 2026, an estimated $55.3K.
  • Atrium Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3138 holding.
  • Legal & General Group first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Legal & General Group's Atrium Therapeutics position peaked at $75.6K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.